Wall Street analyst estimates for Electromed, Inc. (ELMD): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $0.26 | ||
| 2026-08-25 | $0.39 | $0.32 | +23.1% |
| 2026-05-12 | $0.35 | $0.26 | +34.6% |
| 2026-02-10 | $0.32 | $0.27 | +18.5% |
| 2025-11-12 | $0.25 | $0.22 | +13.6% |
| 2025-08-26 | $0.25 | $0.22 | +13.6% |
| 2025-05-13 | $0.21 | $0.20 | +5.0% |
| 2025-02-11 | $0.22 | $0.18 | +22.2% |
Valuation Ratios
| P/E Ratio | 19.72 |
| Price / Book | 4.14 |
| EV / EBITDA | 13.83 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.9M | $28.3M | $31.3M | $32.5M | $35.8M | $41.7M | $48.1M | $54.7M | $64.0M | $73.8M |
| Cost of Revenue | $5.3M | $6.5M | $7.5M | $7.3M | $8.5M | $10.2M | $11.5M | $13.0M | $14.0M | $15.8M |
| Gross Profit | $20.6M | $21.8M | $23.8M | $25.2M | $27.3M | $31.4M | $36.5M | $41.7M | $50.0M | $57.9M |
| Research & Development | $596876 | $251443 | $583311 | $1.1M | $1.7M | $1.4M | $916000 | $656000 | $996000 | $1.3M |
| Selling, General & Admin | $16.4M | $18.8M | $20.4M | $19.9M | $22.4M | $27.1M | $31.6M | $34.5M | $39.1M | $42.7M |
| Operating Expenses | $17.0M | $19.1M | $21.0M | $20.1M | $24.2M | $28.5M | $32.5M | $35.1M | $40.1M | $44.1M |
| Operating Income | $3.6M | $2.7M | $2.8M | $5.1M | $3.1M | $3.0M | $4.0M | $6.6M | $9.9M | $13.9M |
| EBITDA | $4.3M | $3.5M | $3.8M | $5.9M | $3.8M | $3.6M | $4.7M | $7.9M | $11.5M | $15.0M |
| Interest Expense | $66911 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | $3.5M | $2.7M | $2.9M | $5.2M | $3.2M | $3.0M | $4.1M | $7.0M | $10.3M | $14.4M |
| Income Tax | $1.3M | $901000 | $940000 | $1.1M | $805000 | $692000 | $920000 | $1.9M | $2.7M | $3.1M |
| Net Income | $2.2M | $1.8M | $2.0M | $4.2M | $2.4M | $2.3M | $3.2M | $5.2M | $7.5M | $11.3M |
| EPS | $0.27 | $0.23 | $0.24 | $0.50 | $0.28 | $0.27 | $0.37 | $0.60 | $0.90 | $1.37 |
| EPS (Diluted) | $0.26 | $0.22 | $0.23 | $0.47 | $0.27 | $0.26 | $0.36 | $0.58 | $0.86 | $1.30 |
| Shares Outstanding (Diluted) | $8.5M | $8.6M | $8.6M | $8.8M | $8.9M | $8.8M | $8.7M | $8.9M | $8.7M | $8.7M |
Price
| Price | $26.15 |
| Market Cap | $217M |
| Exchange | AMEX |
| Country | US |
Related companies: CATX · HSDT · INFU · INGN · MXCT · NNOX · OM
Explore sector: Healthcare · Medical - Devices
More sections of ELMD: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks